Related Experiment Videos
Metabolic interaction between fluoxetine and clomipramine: a case report
A E Balant-Gorgia1, C Ries, L P Balant
1Department of Psychiatry, University Hospitals of Geneva, Switzerland.
Pharmacopsychiatry
|January 1, 1996
Summary
Combining clomipramine and fluoxetine in an elderly patient led to high drug levels and cardiac side effects. Discontinuing both antidepressants improved mood and resolved side effects, allowing successful clomipramine monotherapy.
Area of Science:
- Pharmacology
- Clinical Psychiatry
- Drug Metabolism
Background:
- Elderly patients with depression often require pharmacotherapy.
- Combined antidepressant therapy can be complex due to potential drug interactions.
- Therapeutic drug monitoring (TDM) is crucial for optimizing treatment and managing toxicity.
Observation:
- An 83-year-old patient on combined clomipramine and fluoxetine for depression showed poor response and cardiac side effects.
- Blood analysis revealed very high concentrations of clomipramine and its metabolite, desmethylclomipramine, indicating a potential metabolic interaction.
- Discontinuation of both antidepressants led to a gradual decrease in drug levels, improvement in mood, and resolution of cardiac side effects.
Findings:
- A significant metabolic interaction occurred between clomipramine and fluoxetine, leading to subtoxic drug accumulation.
- Fluoxetine likely inhibited the metabolism of clomipramine, increasing its plasma concentration.
- Successful treatment was achieved with clomipramine monotherapy once drug levels normalized.
Implications:
- This case highlights the risk of drug-drug interactions when combining clomipramine with potent CYP450 inhibitors like fluoxetine, especially in the elderly.
- Therapeutic drug monitoring is essential for managing complex antidepressant regimens and preventing toxicity.
- Individualized dosing and careful consideration of drug metabolism are critical for effective and safe antidepressant treatment in older adults.